Table 2.
Association between the endogenous DNA damage level and patients’ clinicopathological characteristics using univariate statistical analysis (N = 74; a cutoff value of 6.34 was used for dichotomization of endogenous DNA damage level measured in the patients’ PBMCs).
| The DNA Damage Level ≤6.34 >6.34 |
|||||
|---|---|---|---|---|---|
| Variable | N | % | N | % | p Value b |
| All patients | 55 | 74.3 | 19 | 25.7 | NA |
| Histology | |||||
| Seminoma | 13 | 65.0 | 7 | 35.0 | 0.37 |
| Nonseminoma | 42 | 77.8 | 12 | 22.2 | |
| Tumor primary | |||||
| Primary GCTs | 54 | 76.1 | 17 | 23.9 | 0.16 |
| Extragonadal GCTs | 1 | 33.3 | 2 | 66.7 | |
| IGCCCG risk group | |||||
| Good risk + adjuvant therapy | 32 | 74.4 | 11 | 25.6 | 0.54 |
| Intermediate + poor risk | 2 | 28.6 | 5 | 71.4 | |
| No. of metastatic site(s) | |||||
| 0 | 14 | 77.8 | 4 | 22.2 | 0.11 |
| 1 to 2 | 35 | 79.5 | 9 | 20.5 | |
| >3 | 6 | 50.0 | 6 | 50.0 | |
| Retroperitoneal lymph node metastases | |||||
| Absent | 17 | 81.0 | 4 | 19.0 | 0.56 |
| Present | 38 | 71.7 | 15 | 28.3 | |
| Mediastinal lymph node metastases | |||||
| Absent | 50 | 78.1 | 14 | 21.9 | 0.11 |
| Present | 5 | 50.0 | 5 | 50.0 | |
| Lung metastases | |||||
| Absent | 46 | 76.7 | 14 | 23.3 | 0.33 |
| Present | 9 | 64.3 | 5 | 35.7 | |
| Liver metastases | |||||
| Absent | 50 | 73.5 | 18 | 26.5 | 1.00 |
| Present | 5 | 83.3 | 1 | 16.7 | |
| Non-pulmonary visceral metastases | |||||
| Absent | 48 | 72.7 | 18 | 27.3 | 0.67 |
| Present | 7 | 87.5 | 1 | 12.5 | |
| S stage a | |||||
| 0 | 21 | 80.8 | 5 | 19.2 | 0.61 |
| 1 | 19 | 76.0 | 6 | 24.0 | |
| 2 | 8 | 61.5 | 5 | 38.5 | |
| 3 | 7 | 70.0 | 3 | 30.0 | |
SEM, standard error of the mean; IGCCCG, International Germ Cell Consensus Classification Group. Values of p ≤ 0.05 are considered statistically significant. a Defined by the IGCCCG criteria: S0, within normal limits; S1, AFP < 1000 ng/mL and/or β-HCG < 5000 mIU/mL and/or LDH < 1.5 U/L upper normal limit; S2, AFP 1000–10,000 ng/mL and/or β-HCG 5000–50,000 mIU/mL and/or LDH 1.5–10 U/L upper normal limit; S3, AFP > 10,000 ng/mL and/or β-HCG > 50,000 IU/mL and/or LDH > 10 U/L upper normal limit. b Univariate analysis.